BG Medicine, Inc. Stock Price

BG Medicine, Inc. engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs, improve patient outcomes and contain healthcare costs in the United States and Europe. The company offers BGM Galectin-3 Test for heart failure, is a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE Test, testing for blood-based analytes related to vulnerable cardiovascular plaque, toward uncovering hidden risk of near-term risk of cardiovascular events, such as heart attack and stroke. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.